Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

150.41 -0.99 (-0.65%)
Streaming Delayed Price Updated: 12:08 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
51 52 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy in June ↗
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
3 Dividend Stocks You Can Buy Without Any Hesitation ↗
The choices are easy with these stocks. 
Via The Motley Fool
News headline image
A Look Into Gilead Sciences' Debt ↗
 
Via Benzinga
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Gilead Sciences Stock: Bear vs. Bull ↗
The S&P 500 has outperformed Gilead over the past five years. 
Via The Motley Fool
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,300 Today ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
3 Undervalued Biotech Stocks to Buy Before They Blast Off ↗
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
News headline image
Stocks Going Ex-Dividend In June 2023 ↗
The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Expert Ratings for Gilead Sciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class ↗
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily
News headline image
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark ↗
On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier. 
Via Investor's Business Daily
News headline image
3 Relatively Safe Stocks to Buy if a Recession Is on the Way ↗
If the economy falters, these stocks should hold up better than most. 
Via The Motley Fool
News headline image
3 Analyst Upgrades That Smart Investors Won’t Ignore ↗
In many cases, analyst upgrades can point investors to opportunities like the ones in the stocks on this list. 
Via InvestorPlace
News headline image
GDC Stock Alert: Why Is GD Culture Group Up 106% Today? ↗
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 ↗
 
Via Benzinga
News headline image
Why Is Guardforce AI (GFAI) Stock Up Today? ↗
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering. 
Via InvestorPlace
News headline image
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100? ↗
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares. 
Via InvestorPlace
News headline image
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play. 
Via Benzinga
News headline image
2 Magnificent Dividend Stocks to Buy Before the Next Recession ↗
The healthcare sector is a good place to find recession-proof stocks. 
Via The Motley Fool
News headline image
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years ↗
Should you buy Gilead Sciences stock despite its poor track record? 
Via The Motley Fool
News headline image
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
News headline image
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits ↗
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.